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Recent studies have focused on elucidating the contri-
bution of individual complement proteins to post-ische-
mic cellular injury. As the timing of complement activa-
tion and deposition after cerebral ischemia is not well
understood, our study investigates the temporal pattern
of C1q accumulation after experimental murine stroke.
Brains were harvested from mice subjected to transient
focal cerebral ischemia at 3, 6, 12, and 24 hr post re-
perfusion. Western blotting and light microscopy were
employed to determine the temporal course of C1q
protein accumulation and correlate this sequence with
infarct evolution observed with TTC staining. Confocal
microscopy was utilized to further characterize the cel-
lular localization and characteristics of C1q deposition.
Western Blot analysis showed that C1q protein begins
to accumulate in the ischemic hemisphere between 3
and 6 hr post-ischemia. Light microscopy confirmed
these findings, showing concurrent C1q protein staining
of neurons. Confocal microscopy demonstrated co-
localization of C1q protein with neuronal cell bodies as
well as necrotic cellular debris. These experiments
demonstrate the accumulation of C1q protein on neu-
rons during the period of greatest infarct evolution. This
data provides information regarding the optimal time
window during which a potentially neuroprotective anti-
C1q strategy is most likely to achieve therapeutic
success. VC 2006 Wiley-Liss, Inc.
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Significant effort has been dedicated to the identifi-
cation of inflammatory mediators whose inhibition can
reduce the extent of brain damage after occlusion of a
major cerebral artery (Fagan et al., 2005). Many such
efforts have focused on modulating the complement cas-
cade, which has been implicated in a wide variety of
pathologic processes (D’Ambrosio et al., 2001). Tissue
subjected to ischemia and reperfusion activates comple-
ment (Vakeva et al., 1994; Collard et al., 1997; Vakeva
et al., 1998; Zhou et al., 2000; D’Ambrosio et al., 2001;
Wada et al., 2001). In stroke, this process may lead to
the expansion of the ischemic core into otherwise viable
penumbral tissue (D’Ambrosio et al., 2001).
The complement cascade incorporates the classical,
alternative, and mannose pathways. The classical arm is
initiated by the deposition of C1 onto the surface of tar-
get cells. C1 is a three-protein complex consisting of
C1q, C1r, and C1s. The largest of these proteins, C1q,
has the unique property of having its own specific
receptors and cellular functions, in addition to its ability
to participate in the formation of a C3-convertase (Ten-
ner, 2001). Thus, cellular deposition of C1q has the
potential to cause tissue injury via a broad array of com-
plement cascade-dependent and independent mecha-
nisms (Tenner, 2001). The precise inciting molecular
event is not entirely clear. Work by Rossen and co-
workers suggested that loss of membrane integrity, caus-
ing exposure of sub-cellular components to the extracel-
lular milieu, attracts C1q, leading to activation of the
downstream effectors of complement (Rossen, 1988;
Kagiyama, 1989). The resulting pro-inflammatory medi-
ators are believed to cause inflammation and tissue injury
in sites remote from the initially injured cells (Chakra-
borti et al., 2000; Gasque et al., 2000).
Recent anti-ischemic strategies have focused on the
classical complement pathway and its downstream influ-
ence on inflammation and reperfusion injury. Our group
found that mice treated with the complement inhibitor
soluble complement receptor-1 (sCR1) experience a
modest reduction in cerebral infarct volume and im-
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provement in neurologic outcome after middle cerebral
artery occlusion (MCAO), presumably in large part
through blockade of the downstream effects of post-is-
chemic cerebral C1q expression (Huang et al., 1999).
Nevertheless these studies did not definitively confirm
the time course of this upregulation. Gaining insight into
the temporal sequence of events in cerebral ischemia is
critically important for targeting potential treatments, as
many stroke therapies seem to have a narrow therapeutic
window. This in turn may explain the failure of several
clinical trials (Gladstone et al., 2002). As the timing of
complement activation after stroke is not well under-
stood, this study investigates the temporal pattern of C1q
accumulation and deposition after experimental murine
stroke, and places this in context of infarct evolution.
MATERIALS AND METHODS
Antibodies and Reagents
Primary antibodies and reagents used included anti-
Microtubule Associated Protein (MAP-2) (Chemicon, Teme-
cula, CA), anti-C1q (Connex GmbH, Martinsried, Germany)
(used for immunohistochemistry), anti-C1q (Quidel Corpora-
tion, San Diego, CA) (used for Western blot), and Neurotrace
640/660 Fluorescent Nissl (Molecular Probes, Eugene, OR).
Secondary antibodies were biotinylated anti-IgG) (Jackson
ImmunoResearch Laboratories, West Grove, PA), Alexa Fluor-
488, 594, or 639 conjugated anti-IgG (Molecular Probes) and
horseradish peroxidase-conjugated anti-IgG (Jackson Immuno-
Research Laboratories).
Mice
All experiments were conducted in a humane manner
in accordance with the guidelines published in the NIH
Guide for the Care and Use of Laboratory Animals, and under
the supervision and approval of the Columbia University
Institutional Animal Care and Use Committee. We utilized
adult male C57BL/6 mice, age 8–10 weeks, weighing
between 22 and 26 g at the time of surgery. Mice were
housed in certified animal care barrier facilities in micro isola-
tor cages with free access to food and water on a 12-hr light/
dark cycle.
Murine Model of Focal Cerebral Ischemia
These studies utilized the intraluminal filament model
described previously, with minor modifications (Connolly
et al., 1996). Briefly, mice were anesthetized, intubated, and
maintained under general inhaled anesthesia on a mechanical
ventilator, with settings demonstrated by serial arterial blood
gasses to maintain normoxia and normocapnia. Middle cere-
bral artery occlusion was carried out by advancing a heat-
blunted, silicon-coated 7-0 nylon suture via the external ca-
rotid artery to the origin of the middle cerebral artery. After
60 min of ischemia, the occluding suture was withdrawn to
establish reperfusion. Mice subjected to sham surgery under-
went an identical operative procedure, without insertion of
the occluding suture.
Transcranial measurements of cerebral blood flow (CBF)
were made using laser-Doppler flowmetry (Periflux System
5000, Perimed, Inc., North Royalton, OH) as described previ-
ously (Connolly et al., 1996), using 0.5 mm flexible fiberoptic
Doppler probes (Perimed) attached with tissue adhesive to the
intact skull over landmarks published previously (2 mm poste-
rior to the bregma, 6 mm to each side of midline). Relative
CBF measurements were made after anesthesia, immediately
after occlusion, before reperfusion, and immediately after reper-
fusion to confirm proper suture placement and adequate re-
perfusion. Strict criteria are utilized to prospectively exclude
animals that do not experience significant CBF drop-off (>70%
of baseline), do not maintain consistent levels of CBF decrease
or do not demonstrate adequate reperfusion (>90% of baseline).
At specified, randomized time points (3, 6, 12, or 24 hr
after MCAO), mice were sacrificed, and their brains were per-
fused by transcardiac injection of ice cold PBS and removed
intact. Sham mice were sacrificed 24 hr post-operatively. Nor-
mal non-operative mice served as uninjured controls.
Western Blot
Mice underwent the focal cerebral ischemia procedure
described above, or sham surgery, and were sacrificed after 3,
6, 12, or 24 hr (n ¼ 1 per time point). The brains were saline
perfused, rapidly harvested in one piece, divided into ipsilateral
(injured) and contralateral (uninjured) hemispheres, and snap-
frozen in liquid nitrogen. Samples were suspended in PBS, ho-
mogenized using a motorized glass-Teflon Potter homogenizer
in the presence of protease inhibitor cocktail tablet (Roche,
Basel, Switzerland), and centrifuged at 800–1,000 3 g for 10 min.
The supernatant was then spun at 15,000 3 g to pellet out
cellular debris. Total protein concentration was evaluated with
BCA assay (Pierce Chemical, Rockford, IL), and samples were
diluted to a total protein concentration of 1–5 lg/ll.
Fifty lg of total protein per sample were denatured in
SDS with reducing agent, and run on NuPAGE Novex 4–
12% Bis-Tris Gel (Invitrogen, Carlsbad, CA) under reducing
conditions. Protein was transferred to a nitrocellulose mem-
brane using 30 V current applied for 60 min. Membranes
were first stained to determine total protein content using
Ponceau S stain (0.5% Ponceau S, 1.0% glacial acetic acid, in
de-ionized water), followed by imaging using a digital scanner.
After imaging, blots were destained by washing in Tween-Tris
buffered saline (TTBS) (0.1% Tween-20 in 100 mM Tris-CL
[pH 7.5], 0.9% NaCl) for 5 min, and were then washed briefly
with 0.1 M tris buffered saline (TBS), and blocked for 1 hr in
0.1 M TBS containing 5% non-fat dry milk at room tempera-
ture with constant agitation. Membranes were then incubated
with the primary antibody (anti-C1q antibody) in TBS with
0.05% Tween-20 (TBST) in 2% nonfat dry milk for 3 hr, and
then washed three times for 5 min each in TBST. After wash-
ing, membranes were incubated with horseradish peroxidase-
conjugated rabbit anti-goat secondary antibody for 30 min and
then washed three times for 5 min in TBST, and twice in
TBS. Immunoreactive bands were then detected using a chem-
iluminescence kit (Roche), and membranes exposed to X-ray
film (Eastman Kodak, Rochester, NY). Protein loading was
assessed by probing the blot for beta actin, with densitometry
indicating no significant differences in loading between the
various lanes.
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Immunohistochemistry
Mice underwent the focal cerebral ischemia procedure
described above and were sacrificed after 3, 6, or 24 hr (n ¼ 3
per time point). The brains were saline perfused, rapidly har-
vested in one piece, and fixed in 4% paraformaldehyde for 12 hr
at 48C. Brains were then incubated in 15% sucrose for 1 hr, fol-
lowed by overnight incubation in 30% sucrose. Next, brains
were frozen in optimal cutting temperature (OCT) compound
on dry ice then placed at 808C. Coronal sections (10 lm)
were cut using a cryostat and washed twice in ice cold PBS.
For light microscopy, sections were incubated in 0.3%
peroxidase in 70% methanol for 30 min. Sections (10 lm)
were then blocked with the secondary antibody appropriate
serum (10% donkey or goat serum) with 0.2% Triton X-100
for 90 min at room temperature, followed by biotin blocking
using a commercial kit. Primary antibodies were diluted in
PBS with 5% normal serum, 0.3% Triton X-100. The tissue
was blocked in 10% donkey serum, followed by incubation
with the primary antibody for 90 min at room temperature.
Sections were washed and incubated with the biotinylated
secondary antibodies for 1 hr, followed by incubation with
peroxidase linked avidin-biotin complex (Elite ABC kit, Vec-
tor Laboratories, Burlingame, CA) for 1 hr. The reaction
product was visualized with diaminobenzidine and hydrogen
peroxide. Slides were then mounted and visualized by an ob-
server blinded to the recovery duration.
For immunofluorescence staining, 10-lm sections were
blocked with the secondary antibody appropriate serum (10%
donkey or goat serum) with 0.2% Triton X-100 for 1.5 hr at
room temperature. Primary antibodies were diluted in PBS
with 5% normal serum containing 0.3% Triton X-100. The
tissue was blocked in 10% donkey serum, followed by incuba-
tion with the primary antibody for 90 min at room tempera-
ture. Sections were washed and incubated with fluorochrome-
conjugated secondary antibodies for 1 hr. Nissl staining (20 min,
room temperature) was used for counterstaining. Sections were
then mounted on slides in Vectashield (Vector Laboratories) and
visualized using a Bio-Rad 2000 confocal laser-scanning device
attached to a Nikon E800 microscope.
Semi-quantitative analysis of the immunohistochemical
images was carried out to quantify the total amount of comple-
ment immunostaining in the infarct. Images were captured
under identical fluorescence and magnification settings. Multi-
ple (typically 10–15 images/slide) non-overlapping medium
power fields (403 objective with 13 zoom) were imaged to
cover the entire infarct area. Images were captured and saved in
TIFF format to maintain data quality. Adobe Photoshop v5.5
was then used to split the RGB channels, and the contrast and
brightness for the green and blue channels were both set to
100. These modified channels were then merged leaving only
the red channel contribution to the image (representing com-
plement component staining). These modified images were
then converted to 8-bit gray scale, and analyzed using Image
Pro Plus 4.5 (Media Cybernetics, Silver Spring, MD) software.
The percentage area occupied by positive immunostaining was
calculated for each image and the mean value for each animal
was determined by averaging values from all images taken from
that animal. Because of the use of medium power fields, values
for amount of immunostaining calculated using this method
typically range from 0–2.5% of the field covered, depending on
antibody and reagent characteristics. Data presented represent
an average of the mean values for each animal.
Several controls were used to confirm the validity of
complement staining. Primary antibody specificity was con-
firmed by visualizing both unstained infarcted tissue from
C57Bl/6 wild-type mice and wild-type tissue incubated with
secondary antibodies without primary antibodies using confo-
cal microscopy. To further confirm complement antibody
specificity, infarcted tissue from C57Bl/6 wild-type mice
stained with primary antibodies was blocked with purified
Human C1q protein (Quidel Corp, San Diego, CA). Peptide
blocking abolished complement antibody staining (not
shown). Infarcted brains from C1qa (/) knockout mice
(Botto et al., 1998) were immunostained for C1q (not
shown). The lack of immunostaining seen in these brains sug-
gested that the complement staining in wild-type brains
resulted from in vivo complement deposition, as opposed to
artefactual deposition of complement in necrotic brain tissue
from the blocking serum.
One millimeter sections utilized for triphenyltetrazolium
chloride (TTC) staining were immersed in 2% TTC in 0.9%
saline and incubated for 25 min at 378C. TTC stains of adja-
cent tissue sections were used to confirm infarct localization,
and the entire ipsilateral and contralateral slices were visually
searched for immunopositivity. For confocal microscopy, the
necrotic core was further identified by the regional loss of
MAP-2 immunopositivity, which has been demonstrated to
be an early immunochemical marker of ischemic neuronal
injury (Collard et al., 1997). Cells were identified as neurons
based on morphology and size in light microscopy, and based
on the presence of remnant MAP-2 immunopositivity sur-
rounding Nissl stained nuclei in fluorescent microscopy.
Statistical Analysis
Between-group analyses of semi-quantitative immuno-
staining data at the various time points were carried out utiliz-
ing one-way analysis of variance (ANOVA). All values are
expressed as means 6 SE, with P < 0.05 considered statisti-
cally significant.
RESULTS
C1q Protein Begins to Accumulate in the Brain
Between 3 and 6 hr After Ischemic Injury
Western blots of homogenated mouse brains
probed with a polyclonal anti-C1q antibody yielded two
prominent bands (Fig. 1). The lower molecular weight
band, which is centered around 30 kD, has been well-
characterized by others, and represents 3 closely clustered
bands of the three C1q sub-components (C1q-a [34
kD], C1q-b [32 kD], C1q-g [25 kD]) (Reid and Porter,
1976; Loos, 1983). The higher molecular weight band is
located above the 60 kD marker, and likely is produced
by the closely clustered bands of unreduced a-b (65 kD)
and g-g (63 kD) dimers described by Loos (1983).
No visually or densitometrically apparent differen-
ces were observed in the intensity of bands at 30 kD of
the ipsilateral and contralateral hemispheres at any time
C1q Deposition in Cerebral Ischemia 885
Journal of Neuroscience Research DOI 10.1002/jnr
point. In contrast, C1q protein began to accumulate in
the ipsilateral hemisphere of mice by 6 hr, as manifested
by a marked increase in the intensity of the band near
60 kD, suggesting an accumulation of the unreduced
protein dimers. This band was also prominent in the
ipsilateral hemispheres of mice 12 and 24 hr after onset
of ischemia. This band was not seen in any homogenates
from the contralateral hemispheres. Densitometric analy-
sis of the beta-actin bands indicated that the total protein
content of each lane did not differ.
C1q Deposits in the Brain Parenchyma During
a Period of Significant Infarct Evolution
Consistent with the temporal pattern of C1q accu-
mulation in ischemic brain tissue observed by western
blot, evidence of cellular C1q deposition in the brain
was absent at 3 hr post-ischemia as detected by light
microscopy (Fig. 2D). At 6 hr post-injury, however,
C1q immunopositive cells resembling neurons were
detected throughout much of the infarct area (Fig. 2E).
By 24 hr, C1q deposition was more widespread; how-
ever the greatest increase in C1q positively staining
structures occurred between 3 and 6 hr (Fig. 2F).
TTC staining of mouse brains at 3 hr after MCAO
showed a limited extent of cerebral infarction, which
incompletely involved portions of the striatum and neo-
cortex, and was mainly located in the middle coronal sec-
tions through the striatum and rostral thalamus, which in
this model are destined to have the most extensive infarcts
(Fig. 2A). By 6 hr, the cerebral infarct was far more
extensive, and had more uniformly involved these central
regions, with only a slight interval increase in infarct
extent observed between 6 and 24 hr (Fig. 2B,C).
C1q is Found on Neurons and Neuronal
Remnants After 6 hr
Similar to the pattern observed using light micros-
copy, immunofluorescent staining for C1q in brains of
wild-type mice at 6 and 24 hr post-ischemia showed
widespread staining for components in the infarcted
region of the ipsilateral cortex, that was largely not seen
at 3 hr (Fig. 3A–I). C1q was frequently found to co-
localize with microtubule associated protein (MAP-2) on
cells in the infarcted cortex, implying that complement
Fig. 2. Temporal pattern of C1q deposition and the relation to
infarct evolution. Immunohistochemical time course demonstrating
temporal pattern of complement component C1q deposition in the
ipsilateral neocortex at 3, 6, and 24 hr after ischemic injury, using
light (D–F) microscopy. Representative coronal slices through the
center portion of the MCA territory stained with TTC are provided
for comparison (A–C). C1q deposition was not found in any
observed sections at 3 hr post-ischemia. Subsequent neuronal deposi-
tion of both proteins was routinely found at 6 hr, and became wide-
spread throughout the infarct by 24 hr. A significant interval expan-
sion of the infarct was found to occur between these time points as
well. Scale bar ¼ 30 lm.
Fig. 1. Western blot of homogenated cerebral tissue from un-oper-
ated and sham-operated control mice, as well as mice sacrificed at 3,
6, 12, and 24 hr after the onset of ischemia, probed with polyclonal
anti-C1q antibody. The left and right lanes for each time point rep-
resent specimens taken from the contralateral (uninjured) and ipsilat-
eral (injured) hemispheres respectively. The control lane consists of
tissue taken from one hemisphere of an un-operated mouse.
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accumulation occurs in neurons. Some complement im-
munostaining was identified on diffuse material that
likely represents necrotic cellular debris. Semi-quanti-
tative analysis of this immunofluorescence showed a dif-
ference in immunopositivity between the three groups
(3 hr: 0.0397 6 0.0154, 6 hr: 0.458 6 0.105, 24 hr:
0.497 6 0.142; ANOVA P ¼ 0.05) (Fig. 4).
DISCUSSION
Western blot analysis demonstrates that C1q begins
to accumulate in the brains of mice between 3 and 6 hr
after the onset of cerebral ischemia. This corresponds
temporally to an interval increase in neuronal C1q deposi-
tion as evidenced by immunohistochemistry, and was
confirmed by semi-quantitative analysis of C1q immuno-
fluorescence. Post-ischemic neuronal C1q accumulation
after 24 hr of reperfusion has been noted in prior investi-
gations in both global and focal ischemia models (Huang
et al., 1999; Schafer et al., 2000). This report represents
the first characterization of complement deposition at
early time points (3 and 6 hr) after focal reperfused stroke.
Similar investigations in other tissues, such as myocardium
and intestine, have showed complement immunopositivity
somewhat earlier than 3 hr post-ischemia (Vakeva et al.,
1998; Zhao et al., 2002). The reason for this minor varia-
tion is not clear, but may reflect differences in the experi-
mental models or physiologic differences in complement
upregulation between organ systems.
Of note, post-ischemic cerebral C1q deposition cor-
relates temporally with the period of greatest infarct evo-
lution as assessed by TTC staining. Determining the cause
and effect in this sequence is difficult. Given the observa-
tion that C1q deposition in ischemic myocardium likely
results from a loss of membrane integrity and exposure of
sub-cellular components (Rossen, 1988), neuronal C1q
deposition may well result from a process of expanding
cell death.
Interestingly, the observed onset of complement
deposition coincides temporally with the period of
blood–brain barrier breakdown reported in other studies
(Belayev et al., 1996). The cell-specific origin of post-
ischemic complement synthesis that leads to C1q accu-
mulation in the brain is not known. Whereas the liver is
thought to be principally responsible for complement
synthesis, it has been discovered recently that numerous
extrahepatic cells are capable of complement production
(Morgan and Gasque, 1996, 1997). Various brain cells,
including neurons and glia, produce mRNA for the
entire complement cascade in vitro (Gasque et al., 1992,
1993; van Beek et al., 2003). Furthermore, diverse forms
Fig. 3. Immunofluorescence imaging for
C1q. Confocal images taken from in-
farcted neocortex depict colocalization of
C1q with neuronal processes, as well as
necrotic cellular debris. Images are de-
rived from sections harvested at 3 hr (A,
D, G), 6 hr (B, E, H), and 24 hr (C, F,
I) post-reperfusion. Nissl staining is re-
presented in blue, MAP-2 staining is
represented in green, and C1q is stained
in red, colocalized cells stain yellow. The
channels have been split to clarify the
colocalization. Scale bar ¼ 30 lm.
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of acute brain injury, including cerebral ischemia, seem
to upregulate complement proteins, notably C1q, as
demonstrated by an investigation that demonstrated
microglial synthesis of C1q after transient global cerebral
ischemia (Schafer et al., 2000). Given the large pool of
available complement protein in the blood stream, it is
likely that a significant portion of the cerebral C1q pro-
tein observed in our model between 3 and 6 hr after is-
chemic onset enters with the loss of blood–brain barrier
integrity (Belayev et al., 1996).
In summary, we present evidence that C1q accu-
mulates in the brain somewhat later than in other organ
systems, and occurs during a period (3–6 hr post-ische-
mia) of rapid infarct evolution. These data provide infor-
mation regarding the optimal time window during
which a neuroprotective strategy targeting complement
activation is most likely to achieve therapeutic success.
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